Johnson & Johnson Stock Trending Higher Among Analysts

Johnson & Johnson (JNJ) stock has risen 53.6% over the past 12 months, adding 5.2% in the last month while slipping a modest 0.1% over the past week. Wall Street’s analysts are moderately bullish, with a consensus “ModerateBuy” rating and a 12‑month average price target of $235, compared with a last closing price of $218.49. That target suggests analysts see further upside ahead, even after the stock’s strong run over the past year.

Behind this optimism is confidence in Johnson & Johnson’s ability to keep its growth momentum going. The company recently delivered solid fourth‑quarter results, with revenue of $24.6 billion coming in ahead of Street expectations. Management’s initial 2026 guidance points to adjusted operational revenue growth of 5.7%–6.7%, translating to sales of $99.5 billion–$100.5 billion, and potentially $100.0 billion–$101.0 billion when including a foreign‑exchange tailwind. J&J also projects at least a 50‑basis‑point improvement in its adjusted operating margin in 2026, despite planned heavier investment in new product launches and its pipeline.

Analyst Josh Jennings reiterated his Buy rating on Johnson & Johnson on January 22, 2026, and raised his price target to $250, implying notable upside from current levels. Jennings argues that J&J is well positioned to generate sustained momentum, with its Pharmaceuticals and Medical Devices franchises expected to carry the strength seen in the second half of 2025 into 2026 and beyond. He bases his $250 target on 20 times projected 2027 earnings per share, and notes that 2026 EPS guidance of $11.43–$11.63—helped modestly by FX—already sits above prior Street expectations at the midpoint.

Jennings also highlighted the moving parts within J&J’s Innovative Medicine business. Growth in 2026 is expected to be driven by Tremfya in Immunology, oncology drugs Darzalex, Carvykti, and Erleada, and Spravato in Neuroscience. Newly launched products like Rybrevant/Lazcluze in lung cancer and Caplyta as an adjunctive treatment for major depressive disorder are expected to contribute more as the year progresses. Offsetting these tailwinds, the company faces ongoing erosion of Stelara, new generic competition for Simponi and Opsumit, medtech tariffs of about $500 million, and the financial impact of its voluntary agreement with the U.S. government, which management expects to be spread evenly over 2026.

Adding to the bullish camp, analyst Vamil Divan reiterated his Buy rating on Johnson & Johnson on January 23, 2026, with a price target of $240. While the report fragment offers limited detail, the confirmation of a Buy stance and a target above the current market price reinforces the broader Wall Street view that J&J’s shares still have room to climb. With a consensus ModerateBuy rating and clustered targets in the $235–$250 range, investors watching Johnson & Johnson may see the stock as a large‑cap healthcare name that, according to these analysts, still offers potential upside alongside a diversified and evolving product portfolio. Never miss a stock rating. Find all the latest ratings on TipRanks’ Top Wall Street Analysts page.